AU2023212896A1 - Antibody against btla and uses thereof - Google Patents

Antibody against btla and uses thereof Download PDF

Info

Publication number
AU2023212896A1
AU2023212896A1 AU2023212896A AU2023212896A AU2023212896A1 AU 2023212896 A1 AU2023212896 A1 AU 2023212896A1 AU 2023212896 A AU2023212896 A AU 2023212896A AU 2023212896 A AU2023212896 A AU 2023212896A AU 2023212896 A1 AU2023212896 A1 AU 2023212896A1
Authority
AU
Australia
Prior art keywords
seq
sequence
antibody
antigen
monoclonal antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023212896A
Other languages
English (en)
Inventor
Francisco Adrian
Juying Li
Liang SCHWEIZER
Bingqing Shen
Qian Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hifibio Inc
Original Assignee
Hifibio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hifibio Inc filed Critical Hifibio Inc
Publication of AU2023212896A1 publication Critical patent/AU2023212896A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Transplantation (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2023212896A 2022-01-29 2023-01-29 Antibody against btla and uses thereof Pending AU2023212896A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2022/075109 2022-01-29
CN2022075109 2022-01-29
PCT/CN2023/073699 WO2023143564A1 (en) 2022-01-29 2023-01-29 Antibody against btla and uses thereof

Publications (1)

Publication Number Publication Date
AU2023212896A1 true AU2023212896A1 (en) 2024-08-22

Family

ID=87470720

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023212896A Pending AU2023212896A1 (en) 2022-01-29 2023-01-29 Antibody against btla and uses thereof

Country Status (12)

Country Link
US (1) US20250388673A1 (https=)
EP (1) EP4469482A4 (https=)
JP (1) JP2025504543A (https=)
KR (1) KR20240139083A (https=)
CN (1) CN118871465A (https=)
AR (1) AR128377A1 (https=)
AU (1) AU2023212896A1 (https=)
CA (1) CA3250219A1 (https=)
IL (1) IL314579A (https=)
MX (1) MX2024009309A (https=)
TW (1) TW202340253A (https=)
WO (1) WO2023143564A1 (https=)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2097447A4 (en) * 2006-11-15 2010-12-29 Medarex Inc HUMAN MONOCLONAL ANTIBODIES AGAINST BTLA AND METHODS OF USE
BR112012007875A2 (pt) * 2009-07-31 2016-11-22 Medarex Inc anticorpos totalmente humanos para btla
MX2018010295A (es) * 2016-02-26 2019-06-06 Inst Nat Sante Rech Med Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos.
CN110790837A (zh) * 2018-08-02 2020-02-14 上海君实生物医药科技股份有限公司 抗btla抗体

Also Published As

Publication number Publication date
WO2023143564A1 (en) 2023-08-03
EP4469482A4 (en) 2026-05-06
AR128377A1 (es) 2024-04-24
TW202340253A (zh) 2023-10-16
US20250388673A1 (en) 2025-12-25
IL314579A (en) 2024-09-01
JP2025504543A (ja) 2025-02-12
MX2024009309A (es) 2024-08-27
CA3250219A1 (en) 2023-08-03
EP4469482A1 (en) 2024-12-04
KR20240139083A (ko) 2024-09-20
CN118871465A (zh) 2024-10-29

Similar Documents

Publication Publication Date Title
US20240218076A1 (en) Therapeutic antibodies
CA2977621C (en) Antibody binding to tfpi and composition comprising the same
JP2018536624A (ja) 治療用ｃｄ４７抗体
US12110329B2 (en) Anti-BTLA antibody
JP2018536401A (ja) 抗ｐｄ−ｌ１抗体、その抗原結合フラグメントおよびその医療用途
KR20250044359A (ko) 항-ccr8 항체 및 사용 방법
CN114096275B (zh) 新型bssl抗体
EP4132582A1 (en) Targeted reduction of activated immune cells
WO2023143564A1 (en) Antibody against btla and uses thereof
JP2025503707A (ja) ガレクチン－１０抗体
HK40114352A (zh) 针对btla的抗体及其用途
RU2826992C2 (ru) Новые антитела к bssl
CA3169155C (en) Anti-human cd19 antibodies
JP2026071208A (ja) Ｂｃｍａに結合する多重特異性抗体
EA050239B1 (ru) Мультиспецифические антитела, связывающиеся с bcma
HK40062205A (en) Novel bssl antibodies